In conclusion, while these preclinical studies have been essential for identifying therapeutic areas for OCA and have shown a potential role for FXR agonism in modulating liver fibrosis (this finding has been confirmed in clinical trials), the effect exerted by OCA on lipid metabolism is less consistent (Figure 3). This evidence concerns the gene NR1H4 and Hepatic fibrosis.